Middle East and Africa Blood Coagulants Market is Expected to Grow at a CAGR of 9.5% By 2022

Middle East and Africa Blood Coagulants Market Information, by Drug Class (Coagulation Factor (Plasma-derived Factors

PUNE, MAHARASHTRA, INDIA, May 2, 2017 /EINPresswire.com/ -- Middle East and Africa Blood Coagulants Market Information, by Drug Class (Coagulation Factor (Plasma-derived Factors (Factor VIII and IX, Von Willebrand Disease Factor, Prothrombin Complex and others) and Recombinant Coagulation Factors (Factor VIII and IX, Von Willebrand Disease Factor, Prothrombin Complex and others)), Vitamin K analogues, Fibrinogen Analogues and others), by Clinical Indications (Accidents, Surgery, Hemophilia and Others) - Forecast till 2022

Blood coagulants are natural and synthetic substances which are useful in blocking the bleeding caused due to surgery, accidents, wounds, and disorders such as hemophilia. These drugs are included in the list of essential medicines of World Health Organization (WHO) and many countries. The market for blood coagulants is rising at a good rate due to several factors such as rise in accidents and surgeries, growth of geriatric population, growth of screening for hemophilia patients etc. The rising rates of cancer has created need for chemotherapy treatment which results in bone marrow depression and bleeding tendencies which require infusion of natural coagulant factors derived from blood. The excellent reimbursement for these class of drugs is also driving the market.
The market restraints are special requirements for storage and processing of coagulants, risks of adverse reactions which may be life threatening and concern of infections with coagulants derived from whole blood. Strict regulatory requirements regarding the manufacturer and use of these class of drugs is also hampering the market. The latest market trends include increasing use of advanced technology such as freeze dried coagulant products, use of recombination technology etc. The market is oligopolistic with a few players dominating the scene. The entry barriers are high for new firms and the switching costs for patients is high as there is considerable difference between same product manufactured by different players. The blood coagulant market favors companies with strong biotechnological skills and research and development pipeline. It is also a sector requiring specialized infrastructure and skills thereby providing ample opportunities for contract manufacturing.

Request for sample report at https://www.marketresearchfuture.com/sample_request/2743 .

The Middle East and Africa blood coagulants market has been evaluated as a growing market and it is expected that the market will touch moderate growth figures in future. The Middle East and Africa blood coagulating drugs market is expected to grow with CAGR of ~9.5% during the forecast period. The growth will be primarily led by the need of unmet medical needs and rising incomes of the population.

The major participants of this market are:

- Shire Plc.
- Novo Nordisk
- Bayer AG
- Pfizer Inc.
- Octapharma
- Biogen Inc.
- CSL Behring

Browse complete report at https://www.marketresearchfuture.com/reports/blood-coagulants-market-2743 .

Depending on geographic region, blood coagulants market is segmented into following countries: UAE, Egypt, Saudi Arabia, Kuwait, Qatar and Oman. UAE is the largest market followed by Egypt. Another market with a high growth rate is Saudi Arabia due to rise in health expenditure of government and the rise in disposable income. Algeria and South Africa lead the other African nations due to better performance in health sector. However the future market will be led by the poor developed parts of Africa due to large unmet needs.
Middle East and Africa blood coagulants market has been segmented on the basis of drug class which comprises of coagulation factor which is further sub-segmented into plasma derived and recombinant coagulation factor; vitamin K analogues, fibrinogen analogues and others. On the basis of clinical indications; market is segmented into accidents, surgery, hemophilia and others.

UAE is the largest market for blood coagulant drugs in Middle East and Africa's market of blood coagulating drugs closely followed by Egypt. Another market that has witnessed good growth rates is Saudi Arabia, because of the greater expenditure on health by the local government and the rise in per capita income of the people. Noteworthy markets in Africa include South Africa and Algeria. The demand for these products have given rise to many biotechnological firms especially in India. The rest of Africa market is however the fastest growing with a huge unmet medical needs.
The report for Middle East and Africa Blood Coagulants Market of Market Research Futurecomprises extensive primary research along with the detail analysis of qualitative as well as quantitative aspects by various industry experts, key opinion leaders to gain the deeper insight of the market and industry performance. The report gives the clear picture of current market scenario which includes historical and projected market size in terms of value and volume, technological advancement, macro economical and governing factors in the market. The

report provides detail information and strategies of the top key players in the industry. The report also gives a broad study of the different market segments and regions.

Akash Anand
Market Research Future
+1 646 845 9312
email us here
